- Report
- October 2024
- 190 Pages
Global
From €3389EUR$3,545USD£2,837GBP
€3766EUR$3,939USD£3,152GBP
- Report
- April 2025
- 183 Pages
Global
From €4733EUR$4,950USD£3,962GBP
- Drug Pipelines
- July 2024
- 60 Pages
Global
From €1195EUR$1,250USD£1,000GBP
- Report
- May 2024
- 128 Pages
Global
From €6214EUR$6,499USD£5,201GBP
- Report
- May 2024
- 136 Pages
Global
From €6214EUR$6,499USD£5,201GBP
- Report
- June 2024
- 200 Pages
Global
From €7601EUR$7,950USD£6,363GBP
- Report
- June 2024
- 200 Pages
Global
From €7601EUR$7,950USD£6,363GBP
- Report
- June 2024
- 200 Pages
Global
From €7601EUR$7,950USD£6,363GBP
- Report
- August 2022
- 119 Pages
Global
From €4302EUR$4,500USD£3,601GBP
- Clinical Trials
- February 2024
- 80 Pages
Global
From €1912EUR$2,000USD£1,601GBP
- Report
- July 2023
- 243 Pages
Global
From €7171EUR$7,500USD£6,002GBP
- Drug Pipelines
- August 2022
- 60 Pages
Global
From €1195EUR$1,250USD£1,000GBP
- Report
- January 2022
- 60 Pages
Global
From €3777EUR$3,950USD£3,161GBP
- Report
- January 2022
- 60 Pages
Global
From €3777EUR$3,950USD£3,161GBP
- Report
- January 2022
- 60 Pages
Global
From €3777EUR$3,950USD£3,161GBP
- Report
- January 2022
- 60 Pages
Global
From €3777EUR$3,950USD£3,161GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1912EUR$2,000USD£1,601GBP
- Report
- July 2022
- 68 Pages
Global
From €3342EUR$3,495USD£2,797GBP
- Report
- August 2022
Global
From €755EUR$790USD£632GBP
- Report
- May 2023
- 77 Pages
Global
From €3500EUR$3,921USD£3,032GBP

Vasculitis is a group of diseases that cause inflammation of the blood vessels. It can affect any organ in the body, but is most commonly seen in the heart, lungs, and kidneys. Vasculitis drugs are used to treat the inflammation and reduce the risk of organ damage. These drugs are typically immunosuppressants, which work by suppressing the immune system and reducing inflammation. Common vasculitis drugs include corticosteroids, cyclophosphamide, and methotrexate.
In addition to these drugs, there are also biologic agents, such as rituximab and tocilizumab, which are used to treat more severe cases of vasculitis. These drugs are designed to target specific parts of the immune system, and are often used in combination with other treatments.
The vasculitis drug market is an important part of the cardiovascular drug market, as it provides treatments for a wide range of conditions. Companies in this market include Pfizer, Merck, AbbVie, and Bristol-Myers Squibb. Show Less Read more